Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature
- 7 October 2016
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 19 (1) , 21-34
Abstract
Background Ceftriaxone is a third-generation cephalosporin with broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Despite its effectiveness, its use for the treatment of infections in neonatal patients has been limited because of concern about its potential toxicity. Objective Our aim was to review the literature for an association between ceftriaxone and cardiopulmonary events, hyperbilirubinemia, and pseudolithiasis among neonates. Methods We searched PubMed and EMBASE and included studies that evaluated ceftriaxone safety in neonates. Study bias was evaluated in the following domains: exposure measurement, outcome measurement, attrition, generalizability, confounding, statistical analysis, and reporting. Results We included nine studies regarding ceftriaxone side effects, primarily spontaneous reports, published case reports, and small case series. Reports of bilirubin displacement attributed to ceftriaxone included increases in serum bilirubin necessitating antibiotic change in a subset of infants after administration of ceftriaxone. One study described self-resolving biliary sludge after ceftriaxone administration in six of 80 infants. Cardiopulmonary adverse events included a report of eight cardiopulmonary events related to concomitant ceftriaxone–calcium infusion, including seven infant deaths. Additional cardiopulmonary events reported included perinatal asphyxia, pulmonary hypertension, and thrombocytosis. However, the available literature had small sample sizes, poor external validity, and inconsistent outcome ascertainment methods, which made it impossible to estimate the magnitude of risk. Discussion Concomitant administration of intravenous ceftriaxone and calcium-containing solutions should be avoided in neonates. However, further controlled studies are needed to assess whether bilirubin displacement associated with the use of ceftriaxone is clinically relevant, particularly in healthy term and near-term neonates with mild hyperbilirubinemia.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K08AI112506)
This publication has 27 references indexed in Scilit:
- Safety of ceftriaxone sodium at extremes of ageExpert Opinion on Drug Safety, 2008
- Drug Utilisation Review (DUR) of the Third Generation CephalosporinsDrugs, 1995
- Ceftriaxone-bilirubin-albumin interactions in the neonate: An in vivo studyEuropean Journal of Pediatrics, 1993
- Once-Daily Ceftriaxone to Complete Therapy of Uncomplicated Group B Streptococcal Infection in Neonates A Preliminary ReportClinical Pediatrics, 1992
- Outpatient management of selected infants younger than two months of age evaluated for possible sepsisThe Pediatric Infectious Disease Journal, 1990
- Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of ‘free’ bilirubin and erythrocyte-bound bilirubinJournal of Antimicrobial Chemotherapy, 1987
- TRANSIENT FORMATION OF PRECIPITATIONS IN THE GALLBLADDER ASSOCIATED WITH CEFTRIAXONE THERAPYThe Pediatric Infectious Disease Journal, 1986
- Displacement Effect of Ceftriaxone on Bilirubin Bound to Human Serum AlbuminChemotherapy, 1986
- Ceftriaxone—clinical experience in the treatment of neonatesJournal of Infection, 1985
- Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in childrenEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983